Benitec Biopharma Inc.(BNTC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $12.2M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BNTC Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Benitec Biopharma Inc. (BNTC), a Healthcare sector company. BNTC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $12.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q1 2026), Benitec Biopharma Inc. reports net income of $-11.9M, free cash flow of $-4.5M. Top institutional holders of BNTC by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, Jupiter Topco, FRANKLIN RESOURCES, based on the most recent SEC filings. BNTC trades on the Nasdaq exchange and files with the SEC under CIK 1808898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Benitec Biopharma Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-11.9M
Free Cash Flow
Q1 2026
$-4.5M
ROIC
Q1 2026
-29.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-74.3% YoYOperating Income
-85.7% YoYEPS (Diluted)
+13.9% YoYTotal Assets
+90.8% YoYOp. Cash Flow
-21.6% YoYFree Cash Flow
-20.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 -100.0% | $75.0K +2.7% | $73.0K +23.7% | $59.0K -42.2% | $102.0K |
| Net Income | $-37.9M -74.3% | $-21.8M -11.2% | $-19.6M -7.4% | $-18.2M -31.2% | $-13.9M -67.8% | $-8.3M |
| Operating Income | $-41.8M -85.7% | $-22.5M -17.9% | $-19.1M -6.9% | $-17.9M -31.3% | $-13.6M -64.2% | $-8.3M |
| EPS (Diluted) | $-1.05 +13.9% | $-1.22 +91.4% | $-14.12 +62.7% | $-37.88 -1072.8% | $-3.23 | — |
| Total Assets | $99.6M +90.8% | $52.2M +1069.6% | $4.5M -25.3% | $6.0M -72.1% | $21.4M +84.5% | $11.6M |
| Operating Cash Flow | $-23.6M -21.6% | $-19.4M -7.7% | $-18.0M -13.3% | $-15.9M -23.9% | $-12.8M -70.3% | $-7.5M |
| Free Cash Flow | $-23.6M -20.5% | $-19.6M -8.7% | $-18.0M -13.2% | $-15.9M -21.9% | $-13.1M -71.1% | $-7.6M |
Get alerted when BNTC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Benitec Biopharma Inc. including:
Top Institutional Holders of BNTC
SUVRETTA CAPITAL MANAGEMENT, LLC
$154.5M11,548,351 shJupiter Topco LLC
$33.1M2,478,547 shFRANKLIN RESOURCES INC
$32.3M2,412,888 shADAGE CAPITAL PARTNERS GP, L.L.C.
$28.4M2,120,672 shRA CAPITAL MANAGEMENT, L.P.
$24.8M1,850,000 shNantahala Capital Management, LLC
$19.9M1,488,371 shBlackRock, Inc.
$18.8M1,407,138 shSimplify Asset Management Inc.
$13.5M1,005,557 shVANGUARD CAPITAL MANAGEMENT LLC
$12.8M954,533 shINFINITUM ASSET MANAGEMENT, LLC
$12.3M923,006 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $154.5M | 11,548,351 |
| Jupiter Topco LLC | $33.1M | 2,478,547 |
| FRANKLIN RESOURCES INC | $32.3M | 2,412,888 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28.4M | 2,120,672 |
| RA CAPITAL MANAGEMENT, L.P. | $24.8M | 1,850,000 |
| Nantahala Capital Management, LLC | $19.9M | 1,488,371 |
| BlackRock, Inc. | $18.8M | 1,407,138 |
| Simplify Asset Management Inc. | $13.5M | 1,005,557 |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.8M | 954,533 |
| INFINITUM ASSET MANAGEMENT, LLC | $12.3M | 923,006 |
More Healthcare Companies
View all Healthcare →Put BNTC on your watchlist
Track score changes the day Benitec Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BNTC a good stock to buy?
13F Pro's AI-powered analysis of Benitec Biopharma Inc. (BNTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BNTC are available on the BNTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BNTC is classified as a small company.
Which hedge funds own BNTC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BNTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Benitec Biopharma Inc.'s investment landscape.